002720 — Kukje Pharma Co Share Price
Last trade - 00:00- KR₩114bn
- KR₩132bn
- KR₩135bn
- 33
- 33
- 29
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.47 | ||
| Price to Tang. Book | 1.49 | ||
| Price to Free Cashflow | 76.81 | ||
| Price to Sales | 0.92 | ||
| EV to EBITDA | 71.85 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.58% | ||
| Return on Equity | -7.97% | ||
| Operating Margin | -1.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 111,121.6 | 130,394.72 | 119,745.57 | 126,583.4 | 135,372.69 | n/a | n/a | 4.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kukje Pharma Co., Ltd, formerly Kukje Pharma Ind. Co., Ltd, is a Korea-based company engaged in the manufacture of pharmaceuticals. The Company’s products are finished products, such as antibiotics, other antibiotics for injection, antifungal and antiviral agents, agents for gastrointestinal tract and liver, muscle relaxants, anti-osteoporotics, corticosteroids, agents for cardiovascular and endocrine systems, ophthalmic agents, remedies for central nervous system (CNS) disorders, remedies for urinary systems, antihistamines, antitussives, cough and cold remedies, non-steroidal anti inflammatory drugs (NSAIDs), antitussive, cough and cold remedies, as well as other over-the-counter (OTC) drugs. It also provides raw materials, such as ceftriaxone sodium sterile, cefuroxime axetil, ceftezole sodium sterile, cefminox sodium sterile, cefuroxime sodium sterile and others.
Directors
- Jae Man Ahn CCE (54)
- Tae Hun Nam CCE (34)
- Yeong Wu Nam CCE (72)
- Yeong Su Chi VPR (57)
- Chan Myeong Park OTH (51)
- Seok Hwan Ahn DRC (52)
- Sun Pyeong Kim NID (49)
- Byeong Jun Lee NID (53)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 27th, 1959
- Public Since
- December 27th, 1975
- No. of Shareholders
- 21,345
- No. of Employees
- 414
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 20,362,502
- Address
- 96-8, Yatap-ro, Bundang-gu, SEONGNAM, 13517
- Web
- https://www.kukjepharm.co.kr
- Phone
- +82 317819081
- Auditors
- Shinhan Accounting Corporation
Upcoming Events for 002720
Similar to 002720
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 21:42 UTC, shares in Kukje Pharma Co are trading at KR₩6,380. This share price information is delayed by 15 minutes.
Shares in Kukje Pharma Co last closed at KR₩6,380 and the price had moved by +46.16% over the past 365 days. In terms of relative price strength the Kukje Pharma Co share price has outperformed the FTSE Developed Asia Pacific Index by +39.86% over the past year.
There is no consensus recommendation for this security.
Kukje Pharma Co does not currently pay a dividend.
Kukje Pharma Co does not currently pay a dividend.
Kukje Pharma Co does not currently pay a dividend.
To buy shares in Kukje Pharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩6,380, shares in Kukje Pharma Co had a market capitalisation of KR₩130bn.
Here are the trading details for Kukje Pharma Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 002720
Based on an overall assessment of its quality, value and momentum Kukje Pharma Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kukje Pharma Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +8.96%.
As of the last closing price of KR₩6,380, shares in Kukje Pharma Co were trading +27.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kukje Pharma Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩6,380.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kukje Pharma Co's management team is headed by:
- Jae Man Ahn - CCE
- Tae Hun Nam - CCE
- Yeong Wu Nam - CCE
- Yeong Su Chi - VPR
- Chan Myeong Park - OTH
- Seok Hwan Ahn - DRC
- Sun Pyeong Kim - NID
- Byeong Jun Lee - NID